Humana Inc.

Humana Inc. (HUM) Market Cap

Humana Inc. has a market capitalization of .

No quote data available.

CEO: James A. Rechtin

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 1981-12-31

Website: https://www.humana.com

Humana Inc. (HUM) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Analyst Sentiment

58%
Buy

From 26 Active Polls

1Y Forecast: $294.57

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$195

Median

$265

High Bound

$441

Average

$295

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$294.57
▼ -15.86% Upside
Low Target
$195.00
-44% Risk
Median Target
$264.50
-24% Mid
High Target
$441.00
26% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HUMANA INC (HUM) — Investment Overview

🧩 Business Model Overview

Humana operates as a managed care organization, earning a regulated premium by enrolling members in government-sponsored health programs and then financing care delivery through a network of contracted providers. The value chain is structured around (1) plan administration and member services, (2) pricing and medical cost forecasting, (3) provider contracting and care management, and (4) risk scoring and reimbursement under government benefit designs. For Medicare Advantage members, Humana competes primarily on quality-related performance metrics (e.g., outcomes and member experience) that influence the level of government-directed funding; for Medicaid, the model is similarly driven by risk-adjusted reimbursement and medical cost management, though eligibility dynamics and program terms can shift more frequently.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly recurring and largely tied to enrollment and government reimbursement mechanics, rather than one-time transactions. The primary monetisation drivers include:
  • Medicare Advantage premiums (major driver): monthly capitation payments vary with plan participation and quality outcomes, plus risk adjustment based on member health status.
  • Medicaid premiums (meaningful contributor): reimbursement is driven by state program terms, eligibility, and risk scoring.
  • Administrative and ancillary revenue: care management services, supplemental offerings, and other health services can augment margins, but the core economic engine remains capitation and medical cost efficiency.
Margin structure is best understood through the spread between government-directed revenue (premium and risk/quality mechanics) and medical costs (hospital, physician, post-acute, and prescription spend). Humana’s monetisation is therefore sensitive to coding accuracy, utilization management, and provider contract outcomes, with incremental operating leverage supported by scaling administration and care management infrastructure.

🧠 Competitive Advantages & Market Positioning

Humana’s moat is primarily built on integrated ecosystem + reimbursement/risk expertise, reinforced by scale-driven cost advantages and operational switching frictions within plan administration.
  • Integrated ecosystem (care management + provider network): Humana’s ability to manage chronic conditions, coordinate post-acute services, and steer utilization supports lower medical cost trend relative to peers—an advantage that is difficult to replicate without comparable clinical operations, provider relationships, and data capabilities.
  • Reimbursement/risk model expertise: Medicare Advantage economics depend heavily on risk adjustment and quality performance. Strong coding practices, documentation processes, and analytics create a durable advantage in maximizing appropriate reimbursement while maintaining compliant operations.
  • Scale and cost advantages: Larger membership pools improve claims analytics, administrative efficiency, and contracting leverage, reducing the cost-to-serve and supporting margin resilience through medical cost cycles.
Competitive benchmarking (industry focus vs. peers):
  • UnitedHealth Group (UNH) / Optum segment: broad managed care and services footprint with integrated provider and analytics capabilities. The contrast lies in scale of services and vertical breadth; Humana’s differentiation remains concentrated in Medicare-focused markets and care delivery coordination.
  • CVS Health (Aetna): similarly participates in Medicare Advantage with a large healthcare services ecosystem. Humana competes through region-specific Medicare scale and plan performance mechanics rather than the same level of retail/pharmacy-driven integration.
  • Centene (CNC) and Molina (MOH): stronger Medicaid/MCO tilt relative to Humana’s Medicare emphasis. Humana’s positioning benefits from the Medicare Advantage quality and risk-adjustment economics that differ materially from Medicaid program structures.
Overall, Humana’s industry focus remains oriented toward government-sponsored coverage with Medicare Advantage as a central earnings platform, where operational excellence, risk-model execution, and provider-network effectiveness determine competitive outcomes.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the growth thesis is supported by structural forces that expand both the addressable member base and the value of operational capability:
  • Medicare demographic tailwind: aging-driven enrollment growth increases the total addressable base for Medicare Advantage and related supplemental coverage.
  • Managed care penetration and plan competition: Medicare Advantage continues to capture share from traditional Medicare where beneficiaries value provider access and coordinated care—benefits that accrue to operators able to manage utilization and maintain quality metrics.
  • Chronic care coordination and post-acute optimization: rising chronic disease prevalence increases demand for care navigation and coordinated utilization management—areas where integrated care operations can improve outcomes and reduce avoidable cost.
  • Quality performance as a compounding lever: quality-star performance can influence reimbursement and member retention, creating a feedback loop where operational investment supports both revenue mechanics and lower cost trend.
  • Data-driven risk and utilization management: improved analytics for documentation, risk capture, and utilization targeting enhances the “revenue-cost spread,” which can compound across enrollment growth.

⚠ Risk Factors to Monitor

Structural threats to the model center on reimbursement policy, medical cost variability, and compliance execution:
  • Regulatory and reimbursement changes: CMS policy updates to risk adjustment, quality benchmarks, or benchmark pricing can compress the revenue-cost spread and require rapid operational adaptation.
  • Star-rating and quality metric volatility: quality performance affects reimbursement and competitive position; deterioration can reduce funding and increase member churn.
  • Medical cost trend and utilization shifts: changes in hospital admission patterns, provider pricing, or utilization intensity can outpace pricing assumptions.
  • Provider contracting and market dynamics: provider consolidation and negotiating leverage can raise cost or restrict network terms.
  • Compliance and coding scrutiny: reimbursement depends on accurate, compliant member documentation; increased oversight can constrain risk capture methods and elevate compliance costs.

📊 Valuation & Market View

The managed care sector is typically valued using a blend of earnings multiples (e.g., P/E) and operating cash flow/earnings quality frameworks (including EV/EBITDA in some analyses). For Humana specifically, valuation sensitivity often centers on:
  • Medical cost trend vs. implied pricing: the sustainability of the revenue-cost spread.
  • Quality outcomes and risk-adjustment execution: how reliably the firm can generate reimbursement under CMS mechanics.
  • Enrollment trajectory and retention: changes in Medicare Advantage and Medicaid participation that affect scale and administrative efficiency.
  • Capital and regulatory risk: the perceived stability of the regulatory regime and the company’s compliance track record.
Market participants generally re-rate the sector when policy risk becomes more or less favorable and when operators demonstrate consistent underwriting discipline and quality performance.

🔍 Investment Takeaway

Humana’s long-term investment case rests on an operating model where scale-driven cost advantages, reimbursement and risk-adjustment expertise, and an integrated care coordination ecosystem support durable control of the medical cost trend and funding outcomes under Medicare Advantage mechanics. The core challenge is maintaining quality and underwriting performance amid policy shifts and medical cost uncertainty—an area where competitive execution and compliance capability matter as much as enrollment growth.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"HUM reported Q1 2026 revenue of $39.65B and net income of $1.186B (EPS $9.85). On a YoY basis versus Q1 2025, revenue rose ~1.05% ($39.65B vs $32.11B) and net income declined ~-4.64% ($1.19B vs $1.24B). QoQ, revenue increased ~21.90% versus Q4 2025 ($39.65B vs $32.52B) while net income increased from a loss of -$0.80B in Q4 2025 to +$1.19B in Q1 2026. Profitability improved sharply QoQ: operating income turned positive (+$1.75B) and net margin expanded to ~2.99% from -2.45% in Q4 2025, though margins remain well below the stronger Q1 2025 net margin of ~3.87%. Cash generation rebounded with operating cash flow of $1.25B and free cash flow of $1.13B in Q1 2026, compared with -$1.65B operating cash flow and -$1.85B free cash flow in Q4 2025. Shareholder payouts were steady on a per-quarter basis: dividends paid were -$0.107B and buybacks were -$0.107B. Balance sheet resilience appears stable with total assets of $55.28B and equity of ~$18.6B; net debt declined to ~$9.04B. Total shareholder returns are modestly negative given the -28.17% 1-year price change (no buyback/dividend offset sufficient to overcome the stock decline). Analyst consensus target (~$225.93) implies upside to the $205.14 price."

Revenue Growth

Positive

Revenue up ~21.9% QoQ ($39.65B vs $32.52B) and up ~1.1% YoY ($39.65B vs $32.11B). Trend shows a recovery after the prior quarter.

Profitability

Neutral

Net income improved from -$0.80B (Q4) to +$1.19B (Q1). YoY net income down ~-4.6%. Net margin expanded to ~3.0% QoQ but is below Q1 2025 (~3.9%).

Cash Flow Quality

Positive

Operating cash flow rebounded to $1.25B and free cash flow to $1.13B in Q1 2026 versus strongly negative levels in Q4 2025.

Leverage & Balance Sheet

Positive

Total assets increased to ~$55.3B and equity was stable near ~$18.6B. Net debt modestly improved to ~$9.0B; interest coverage remains positive (~9.1x).

Shareholder Returns

Neutral

1-year price change is -28.17% (capital appreciation negative). Dividend yield is low (~0.51%); buybacks continued but are unlikely to offset the stock decline.

Analyst Sentiment & Valuation

Positive

Consensus target ~$225.93 versus current ~$205.14 suggests upside, but valuation support is moderate given recent stock underperformance.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Humana enters Q1 2026 “on track” to its Investor Day plan, emphasizing operational and clinical execution alongside disciplined MA pricing. The quarter’s key underwriting signal is IBNR rising ~35% sequentially versus ~22% membership growth, which management attributes to prudent early-year reservation given uncertainty and maintains confidence after end-of-April indicators and early claims completion. The strategic fulcrum is the ‘27 bid cycle: management reiterated a sustainable MA margin of at least 3% in 2028 with progress in 2027, but acknowledged the funding environment lags medical cost trend more than last year—driving the need for benefit adjustments rather than purely relying on efficiencies. Capital actions reinforce balance-sheet resiliency (a $1B junior subordinated note issuance, and >$3B mitigation of 2026 capital contributions), while CenterWell growth accelerates via Max Health and continued home/PC scaling. Net: execution is strong, but the main risk is the worsening funding-vs-trend spread constrained by Stars/TBC dynamics.

AI IconGrowth Catalysts

  • CenterWell primary care expansion via acquisition of Max Health to broaden CenterWell reach into new critical markets
  • Medicaid membership growth of ~50,000 lives driven largely by January starts in Michigan, Illinois, and South Carolina
  • CenterWell primary care patient growth of ~110,000 patients (+22.5% sequential), supported by organic growth plus Max Health integration
  • CenterWell Home: launch of the next phase of skilled nursing facility value-based care model covering an additional 2 million patients

Business Development

  • Max Health acquisition (Florida-based primary care organization) to expand CenterWell into new critical markets
  • Welsh Carson put/call structure tied to clinic cohorts; management discussed potential cash obligations if puts are exercised
  • CenterWell expansion of agnostic pharmacy/clinical volume including a newly announced partnership referenced as coming “earlier this week” (name not provided in transcript)
  • CMS engagement on improved rate notice for stability supporting MA industry health

AI IconFinancial Highlights

  • IBNR increased ~35% sequentially versus total Medicare Advantage membership growth of ~22%; management attributed higher IBNR to prudent claims reserves given early-year timing and expected membership growth
  • Guidance performance described as members performing in line to better than guidance after adjusting for a subdued flu season and winter storms; tracking includes risk scores, APTs, pharmacy claims, and initial medical claims
  • MLR seasonality: 2Q MLR guided slightly above ~91%; Celeste attributed Q1→Q2 change to prior-year PPD levels being higher in Q1’25 than Q1’26
  • Balance sheet: completed $1B junior subordinated notes in March expected to fund 2027 maturities; executed subsidiary reinsurance and legal entity structure changes mitigating over $3B in capital contribution requirements for 2026
  • Capital deployment posture: maintaining dividend levels and limiting share repurchases to amounts necessary to offset dilution from employee stock compensation

AI IconCapital Funding

  • Completed $1B junior subordinated notes (March) expected to fund 2027 maturities
  • Mitigated >$3B in 2026 capital contribution requirements via subsidiary reinsurance and legal entity structure optimization
  • Noncore asset divestiture pipeline to help fund strategic acquisitions; expected to share more over the next several months
  • Share repurchases limited to offset employee stock compensation dilution; dividend levels maintained

AI IconStrategy & Ops

  • Operating model efficiencies: centralizing certain teams, expanding outsourcing, and increasing automation of processes to improve operational efficiency
  • Clinical/Stars execution: early engagement for BY’29 Stars; identifying certain chronic conditions among new members faster to target gap closure
  • Claims cost trend monitoring enhancements: anomaly detection, improved first-time payment accuracy, more frequent cadence monitoring of claims hotspots, and deeper new-member component analysis
  • Pricing/benefit strategy for bids: adjusting benefits to bridge funding vs medical cost trend delta to maintain track toward 2028 sustainable margin commitment

AI IconMarket Outlook

  • Investor Day commitments reiterated: sustainable MA margin of at least 3% in 2028 with progress in 2027
  • Management expects to return to top quartile BY’28 Stars results; no guarantee of October thresholds
  • 2Q MLR guided slightly above ~91%
  • Update timing: management stated it will share more on BY’28 Stars progress in the Q2 earnings call after hybrid season completion

AI IconRisks & Headwinds

  • Medical cost trend continues to outpace program funding, increasing the funding shortfall for the ‘27 bid season versus last year
  • IBNR elevated vs membership growth driven by prudent reserve assumptions early in the year, reflecting uncertainty until later claim development completes
  • TBC limitations constrain the ability to fully rely on Stars-era recovery; management plans to accommodate multiple scenarios given incomplete cost profile visibility
  • Wildcards: although members are tracking in line to better than guidance, management noted winter storms and a subdued flu season as factors already accounted for

Q&A: Analyst Interest

  • Topic: IBNR growth vs membership growth drivers (and conservatism). Management explained IBNR was up ~35% sequentially vs ~22% Medicare Advantage membership growth and said the elevated IBNR reflects prudent early-year claim reserve assumptions tied to membership growth, while April indicators and completed claims remained consistent with those expectations.
  • Topic: Welsh Carson put/call cash obligations timing (cash impact in ‘27/’28). Management said a decision is needed mid-year, would be mindful of broader liquidity needs, and characterized Welsh Carson as a structural value partner. If Welsh Carson exercises puts next year (beginning of Q1), cash obligation is about $1B–$1.5B in 2027; both cohorts are similarly $1B–$1.5B, and outflows are included in the funding plan.
  • Topic: ‘27 bidding strategy and margin protection beyond ‘28 TBC/Stars uncertainty. Management framed bids around (1) achieving normalized ≥3% margin in 2028, (2) member retention as the primary constraint, and (3) growth as a distant third priority. They emphasized multi-year contingency planning under TBC limits and funding-vs-trend gaps, while adjusting benefits thoughtfully by market.

Sentiment: MIXED

Note: This summary was synthesized by AI from the HUM Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Humana Inc. (HUM) Financial Profile